hydroxychloroquine

Summary

Summary: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)

Top Publications

  1. ncbi Hydroxychloroquine: from malaria to autoimmunity
    Ilan Ben-Zvi
    Rheumatology Unit, Zabludowicz Center for Autoimmune Diseases and Department of Internal Medicine F, Sheba Medical Center, Tel Hashomer, Israel
    Clin Rev Allergy Immunol 42:145-53. 2012
  2. ncbi Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders
    Stefania Piconi
    I Divisione Malattie Infettive, H L Sacco, Milan, Italy
    Blood 118:3263-72. 2011
  3. pmc A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:1602-8. 2012
  4. ncbi Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy
    Michel Michaelides
    Oregon Retinal Degeneration Center, Casey Eye Institute, Oregon Health and Science University, Portland, OR 97239 4197, USA
    Arch Ophthalmol 129:30-9. 2011
  5. pmc Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus
    Karim Sacre
    Department of Medicine, Division of Experimental Medicine, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    Arthritis Res Ther 14:R155. 2012
  6. ncbi Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity
    Jonathan S Lyons
    Georgetown University Washington National Eye Center, Washington, DC, USA
    Doc Ophthalmol 118:29-36. 2009
  7. ncbi Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine
    J R O'Dell
    University of Nebraska Medical Center, Omaha 68198 3025, USA
    Arthritis Rheum 44:2235-41. 2001
  8. ncbi Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action
    Steven J Katz
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Curr Opin Rheumatol 23:278-81. 2011
  9. ncbi Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy
    Michael F Marmor
    Eye Institute at Stanford, Stanford University, Palo Alto, California, USA
    Ophthalmology 118:415-22. 2011
  10. ncbi Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients
    Michelle Petri
    Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
    Curr Rheumatol Rep 13:77-80. 2011

Detail Information

Publications260 found, 100 shown here

  1. ncbi Hydroxychloroquine: from malaria to autoimmunity
    Ilan Ben-Zvi
    Rheumatology Unit, Zabludowicz Center for Autoimmune Diseases and Department of Internal Medicine F, Sheba Medical Center, Tel Hashomer, Israel
    Clin Rev Allergy Immunol 42:145-53. 2012
    ..Since then, the beneficial effects of quinine and its more advanced synthetic forms, chloroquine and hydroxychloroquine, have been increasingly recognized in a myriad of other diseases in addition to malaria...
  2. ncbi Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders
    Stefania Piconi
    I Divisione Malattie Infettive, H L Sacco, Milan, Italy
    Blood 118:3263-72. 2011
    ..b>Hydroxychloroquine (HCQ) reduces endosomal TLR signaling; thus, we verified whether HCQ could dampen immune activation and be ..
  3. pmc A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:1602-8. 2012
    This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer.
  4. ncbi Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy
    Michel Michaelides
    Oregon Retinal Degeneration Center, Casey Eye Institute, Oregon Health and Science University, Portland, OR 97239 4197, USA
    Arch Ophthalmol 129:30-9. 2011
    To report the detailed clinical findings of patients with retinal toxicity that developed secondary to the use of hydroxychloroquine sulfate (n = 13), chloroquine phosphate (n = 2), or a combination of the agents (n = 1).
  5. pmc Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus
    Karim Sacre
    Department of Medicine, Division of Experimental Medicine, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    Arthritis Res Ther 14:R155. 2012
    ..Given the known efficacy of hydroxychloroquine (HCQ) in the treatment of SLE, we examined its ability to inhibit such pDC function in vivo.
  6. ncbi Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity
    Jonathan S Lyons
    Georgetown University Washington National Eye Center, Washington, DC, USA
    Doc Ophthalmol 118:29-36. 2009
    ..ERG ring ratios provide a sensitive and objective method to detect ocular toxicity in patients taking hydroxychloroquine (Plaquenil)...
  7. ncbi Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine
    J R O'Dell
    University of Nebraska Medical Center, Omaha 68198 3025, USA
    Arthritis Rheum 44:2235-41. 2001
    To compare the efficacy of minocycline with that of a conventional disease-modifying antirheumatic drug (DMARD), hydroxychloroquine, in patients with early seropositive rheumatoid arthritis (RA).
  8. ncbi Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action
    Steven J Katz
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Curr Opin Rheumatol 23:278-81. 2011
    ..Over the past decade, new theories have been proposed in this regard both for rheumatic disease, as well as related conditions...
  9. ncbi Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy
    Michael F Marmor
    Eye Institute at Stanford, Stanford University, Palo Alto, California, USA
    Ophthalmology 118:415-22. 2011
    The American Academy of Ophthalmology recommendations for screening of chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy were published in 2002, but improved screening tools and new knowledge about the prevalence of toxicity have ..
  10. ncbi Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients
    Michelle Petri
    Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MD 21205, USA
    Curr Rheumatol Rep 13:77-80. 2011
    b>Hydroxychloroquine is used extensively in the treatment of systemic lupus erythematosus, not only for its benefit for cutaneous and musculoskeletal lupus, but also for its role in preventing flares, preventing renal and central nervous ..
  11. ncbi Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers
    E Reed Smith
    Department of Emergency Medicine, George Washington University Medical Center, Washington, DC 20007, USA
    J Emerg Med 28:437-43. 2005
    ..There is very limited data on pediatric hydroxychloroquine overdoses and no reports of toxicity from 1-2 pills, but given its similarity to chloroquine, it also should ..
  12. pmc Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency
    Quentin McAfee
    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 109:8253-8. 2012
    ..Clinical trials are underway combining anticancer agents with hydroxychloroquine (HCQ), but concentrations of HCQ required to inhibit autophagy are not consistently achievable in the clinic...
  13. ncbi Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus
    N Ezra
    Division of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Clin Exp Dermatol 37:327-34. 2012
    Antimalarials, such as chloroquine and hydroxychloroquine, have been used to treat cutaneous and systemic lupus erythematosus for decades with excellent therapeutic efficacy...
  14. pmc Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial
    Nicholas I Paton
    MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, United Kingdom
    JAMA 308:353-61. 2012
    ..Therapies to decrease immune activation might be of benefit in slowing HIV disease progression...
  15. pmc Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus
    Anna Broder
    Division of Rheumatology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA
    J Rheumatol 40:30-3. 2013
    ..b>Hydroxychloroquine (HCQ) has been shown in retrospective studies to decrease aPL titers in laboratory studies, and to decrease ..
  16. ncbi An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis
    Piercarlo Sarzi-Puttini
    Unità Operativa di Reumatologia, University Hospital L Sacco, Via G B Grassi 74, 20157 Milan, Italy
    Rheumatol Int 25:15-22. 2005
    To determine whether a regimen of cyclosporine (CSA) and methotrexate (MTX), or CSA and hydroxychloroquine (HCQ) introduced in early rheumatoid arthritis (RA) can produce a significant improvement in clinical outcome and/or retard ..
  17. ncbi Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients
    Stephanie J Morris
    Geisinger Health System, Danville, Pennsylvania 17822, USA
    Arthritis Care Res (Hoboken) 63:530-4. 2011
    ..This study used an electronic health record to determine if hydroxychloroquine (HCQ) use was associated with an improvement in lipid levels in an inception RA cohort.
  18. pmc Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus
    Aimee O Hersh
    University of California, San Francisco, CA, USA
    Arthritis Rheum 61:13-20. 2009
    ..To compare differences in long-term outcome between adults with childhood-onset (age at diagnosis <18 years) systemic lupus erythematosus (SLE) and with adult-onset SLE...
  19. ncbi The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus
    Claudio Galarza-Maldonado
    Unidad de Enfermedades Reumáticas y Autoinmunes UNERA, Hospital Monte Sinai, Cuenca, Ecuador
    Autoimmun Rev 10:108-11. 2010
    ..In this context, the access to treatments recommended internationally are expensive and limited; therefore, research of methods that make these treatments cheaper is of paramount importance...
  20. ncbi Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects
    Lucinda Aguirre-Cruz
    Departamento de Inmunologia, Instituto Nacional de Neurologia y Neurocirugia, Mexico, D F, Mexico
    AIDS Res Hum Retroviruses 26:339-42. 2010
    b>Hydroxychloroquine (HCQ) anti-HIV activity is well documented...
  21. ncbi Comparable efficacy of standardized Ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study
    Arvind Chopra
    Centre for Rheumatic Diseases CRD, 1988 Convent Street, Hermes Elegance, CAMP, Pune, 411001, India
    Clin Rheumatol 31:259-69. 2012
    b>Hydroxychloroquine sulfate (HCQS) is a popular disease-modifying antirheumatic drug (DMARD) despite modest efficacy and toxicity...
  22. ncbi Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties
    F D Goldman
    Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USA
    Blood 95:3460-6. 2000
    b>Hydroxychloroquine (HCQ), a lysosomotropic amine, is an immunosuppressive agent presently being evaluated in bone marrow transplant patients to treat graft-versus-host disease...
  23. ncbi Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity
    Frank Romanelli
    University of Kentucky College of Pharmacy, 800 Rose Street, Lexington, KY 40536, USA
    Curr Pharm Des 10:2643-8. 2004
    ..Chloroquine and its analog hydroxychloroquine are two inexpensive agents that are widely used for the treatment of malaria and have been shown to achieve ..
  24. ncbi Hydroxychloroquine-induced toxic myopathy causing respiratory failure
    Anita K Siddiqui
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Long Island Jewish Medical Center, New Hyde Park, NY, USA
    Chest 131:588-90. 2007
    Chloroquine and hydroxychloroquine (HCQ) are commonly prescribed antimalarial agents used for a variety of systemic diseases...
  25. ncbi Methimazole-induced lupus erythematosus: a case report
    Li Chieh Wang
    Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan, ROC
    J Microbiol Immunol Infect 36:278-81. 2003
    ..With hydroxychloroquine and levothyroxine, she was free of symptoms after discontinuation of methimazole until now (about 21 months).
  26. pmc Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss
    Kimberly E Stepien
    Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, USA
    Trans Am Ophthalmol Soc 107:28-33. 2009
    To describe spectral-domain optical coherence tomography (SD-OCT) and adaptive optics (AO) imaging in hydroxychloroquine retinal toxicity.
  27. ncbi Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology
    Michael F Marmor
    Ophthalmology 109:1377-82. 2002
  28. ncbi Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine
    D Raoult
    Unite des Rickettsies, Faculte de Medecine, Université de la Mediterranée CNRS, Marseille, France
    Arch Intern Med 159:167-73. 1999
    ..Q fever endocarditis, caused by Coxiella burnetii, is fatal in 25% to 60% of patients. Currently, treatment with a long-term tetracycline and quinolone regimen for at least 4 years is recommended, although relapses are frequent...
  29. pmc Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers
    Jacob H Rand
    Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
    Blood 112:1687-95. 2008
    Treatment with the antimalarial drug hydroxychloroquine (HCQ) has been associated with reduced risk of thrombosis in the antiphospholipid (aPL) syndrome (APS) and, in an animal model of APS, with reduction of experimentally induced ..
  30. ncbi Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine
    Patricia Boya
    Centre National de la Recherche Scientifique, UMR 8125, Institut Gustave Roussy, Pavillon de Recherche 1, 39 rue Camille Desmoulins, F 94805 Villejuif, France
    Oncogene 22:3927-36. 2003
    b>Hydroxychloroquine (HCQ) is a lysosomotropic amine with cytotoxic properties...
  31. ncbi Fundus autofluorescence and spectral domain optical coherence tomography in early detection of Plaquenil maculopathy
    Amy T Kelmenson
    Department of Ophthalmology, University of Florida College of Medicine, Jacksonville, FL 32209, USA
    Eur J Ophthalmol 20:785-8. 2010
    To report fundus autofluorescence (FAF) and spectral-domain optical coherence tomography (SD-OCT) findings in a patient with early hydroxychloroquine maculopathy.
  32. ncbi The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal
    Ioannis Mavrikakis
    Department of Ophthalmology, Athens Eye Hospital, Athens, Greece
    Ophthalmology 110:1321-6. 2003
    To define the risk of hydroxychloroquine (HCQ)-related retinal toxicity in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) who are receiving recommended dosages of the drug (< or =6.5 mg/kg/day).
  33. ncbi Severe hydroxychloroquine myopathy
    Hoda Abdel-Hamid
    Department of Pediatrics, Division of Child Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Muscle Nerve 38:1206-10. 2008
    b>Hydroxychloroquine causes a vacuolar myopathy that is usually of mild to moderate severity. The myopathy may be underrecognized, especially in patients who receive multiple other medications for complex illnesses...
  34. ncbi Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs
    Natalia Pinho de Oliveira Ribeiro
    National Institute for Science and Technology Translational Medicine INCT TM Laboratory of Panic and Respiration, Institute of Psychiatry, UFRJ, INCT TM Electronic address
    Compr Psychiatry 54:1185-9. 2013
    ..This paper aims to investigate the prevalence of anxiety, depression and suicidal ideation in patients with rheumatoid arthritis taking different drugs to control the disease...
  35. ncbi Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio
    Laurence Lagneaux
    Laboratoire d Hematologie Experimentale, Institut Jules Bordet, Brussels, Belgium
    Leuk Lymphoma 43:1087-95. 2002
    We tested the effects of hydroxychloroquine (HCQ), an anti-rheumatic drug, on the viability of chronic lymphocytic leukemia (CLL) cells. HCQ induced a decrease in cell viability in a dose- and time-dependent manner...
  36. ncbi Treatment of so-called idiopathic follicular mucinosis with hydroxychloroquine
    S W Schneider
    Department of Dermatology, Venereology and Allergology, Experimental Dermatology, Medical Faculty Mannheim, Heidelberg Ruprecht Karls University, Mannheim, Germany
    Br J Dermatol 163:420-3. 2010
    ..Six patients with 'idiopathic' FM were treated with hydroxychloroquine (HCQ) at a dose of 200 mg three times daily for 10 days followed by a dose adjusted to the ideal body weight,..
  37. ncbi Ocular toxicity of hydroxychloroquine
    Rodney Tehrani
    Loyola University Medical Center, Maywood, IL 60153, USA
    Semin Ophthalmol 23:201-9. 2008
    This review summarizes the current literature regarding the ocular complications of hydroxychloroquine. Hydroxychloroquine has been used since the 1950s for the treatment of various rheumatic and dermatologic diseases...
  38. ncbi Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature
    Jessica E Nord
    Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, Los Angeles, California, USA
    Semin Arthritis Rheum 33:336-51. 2004
    b>Hydroxychloroquine (HCQ) is extensively used in the long-term treatment of systemic lupus erythematosus (SLE). Although considered by clinicians to be relatively safe, serious side effects have been documented in the literature...
  39. ncbi Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine
    Aisha Lateef
    Department of Medicine, Yong Loo Lin School of Medicine, National University Health System, Singapore, Singapore
    Clin Rheumatol 28:1449-52. 2009
    ..erythematosus who presented with features of AGEP but evolved to AGEP-TEN overlap as an adverse reaction to hydroxychloroquine (HCQ) treatment...
  40. ncbi Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells
    Rayhana Rahim
    Department of Biochemistry, West Virginia University, Morgantown, West Virginia, USA
    Anticancer Drugs 20:736-45. 2009
    The antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have potential applications in cancer treatment...
  41. ncbi Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine
    Philip J Penrose
    Department of Ophthalmology, California Pacific Medical Center, PO Box 7999, San Francisco, CA 94120, USA
    Retina 23:503-12. 2003
    To evaluate macular function using multifocal electroretinography (mfERG) in a cohort of asymptomatic patients taking hydroxychloroquine and a patient with maculopathy secondary to hydroxychloroquine treatment.
  42. pmc Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases
    Gaëlle Leroux
    Ann Rheum Dis 66:1547-8. 2007
  43. pmc Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial
    Sarah R Kingsbury
    Division of Rheumatic and Musculoskeletal Disease and National Institute of Health Research NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds LS7 4SA, UK
    Trials 14:64. 2013
    ..Synovitis is prevalent in OA and is associated with pain. Hydroxychloroquine is used in routine practice for treating synovitis in inflammatory arthritides, such as rheumatoid arthritis...
  44. ncbi Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties
    David C Warhurst
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK
    J Antimicrob Chemother 52:188-93. 2003
    The 4-aminoquinoline drug hydroxychloroquine (HCQ) is reported to be as active as chloroquine (CQ) against falciparum malaria, and less toxic...
  45. ncbi Comparison of screening procedures in hydroxychloroquine toxicity
    Michael F Marmor
    Department of Ophthalmology, Stanford University School of Medicine, Byers Eye Institute at Stanford, 2452 Watson Ct, Palo Alto, CA 94303 5353, USA
    Arch Ophthalmol 130:461-9. 2012
    To compare different screening procedures for hydroxychloroquine sulfate (Plaquenil) toxicity at different stages of damage.
  46. pmc Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
    Vappu Rantalaiho
    Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FI 33521 Tampere, Finland
    Arthritis Res Ther 12:R122. 2010
    ..The aim of this study was to evaluate the radiologic progression beyond that time in patients with early RA initially treated with a combination of three disease-modifying antirheumatic drugs (DMARDs) or a single DMARD...
  47. pmc Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine
    Peter M Izmirly
    Division of Rheumatology, Department of Medicine, New York University School of Medicine, Th 407, New York, NY 10016, USA
    Ann Rheum Dis 69:1827-30. 2010
    ..TLR) signalling in the pathogenesis of neonatal lupus (NL), it was hypothesised that fetal exposure to hydroxychloroquine (HCQ), a TLR inhibitor, might reduce the risk of anti-SSA/Ro/SSB/La antibody-associated cardiac ..
  48. ncbi Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study
    Gianantonio Saviola
    Rheumatology and Rehabilitation Unit, Salvatore Maugeri Foundation IRCCS, Via Ospedale 36, 46042 Castel Goffredo, Mantua, Italy
    Mod Rheumatol 22:256-63. 2012
    ..the efficacy of clodronate for treating active erosive osteoarthritis of the hand and to compare it with hydroxychloroquine. Group A consisted of 24 patients treated for 24 months with clodronate 300 mg i.v...
  49. ncbi Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus
    Frederick Wolfe
    National Data Bank for Rheumatic Diseases and University of Kansas School of Medicine, Wichita, KS 67214, USA
    Arthritis Care Res (Hoboken) 62:775-84. 2010
    b>Hydroxychloroquine (HCQ) retinopathy is of concern because of the potential seriousness of visual loss and the medicolegal consequences of failure to detect toxicity...
  50. ncbi Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy
    Crispin Abarientos
    New York Medical College, Division of Allergy, Immunology and Rheumatology, Munger Pavilion, Valhalla, NY 10595, USA
    Expert Opin Drug Saf 10:705-14. 2011
    The antimalarial drug hydroxychloroquine (HCQ) is widely used to treat various rheumatic diseases...
  51. pmc Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort
    R Willis
    University of Texas Medical Branch, Galveston, USA
    Lupus 21:830-5. 2012
    We sought to determine the effect of hydroxychloroquine therapy on the levels proinflammatory/prothrombotic markers and disease activity scores in patients with systemic lupus erythematosus (SLE) in a multiethnic, multi-center cohort (..
  52. ncbi Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma
    Gustavo H Marin
    CUCAIBA, Ministry of Health, Province of Buenos Aires, Calle 60 y 120, 1900 La Plata, Buenos Aires, Argentina
    Curr Clin Pharmacol 5:246-50. 2010
    ..study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate ..
  53. ncbi [Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome]
    J Szymezak
    Service d Hematologie Biologique, Hopital Europeen Georges Pompidou, AP HP, 20 40, rue Leblanc, 75908 Paris Cedex 15, France
    Rev Med Interne 31:854-7. 2010
    Studies have shown a protective effect of hydroxychloroquine on thrombosis in systemic lupus erythematosus patients...
  54. ncbi Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies
    Ricardo G Espinola
    Department of Microbiology, Morehouse School of Medicine, Atlanta, Georgia 30310 1495, USA
    Thromb Haemost 87:518-22. 2002
    ..The antimalarial drug hydroxychloroquine (HQ) has been used successfully in prevention of postoperative thrombosis and in treatment of patients with ..
  55. pmc Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment
    Elizabeth A Mauldin
    Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 3850 Spruce Street Philadelphia, PA 19104, USA
    Vet Dermatol 21:373-82. 2010
    ..Ciclosporin decreased erythema and arthralgia, but did not halt worsening of lesions. Three dogs received hydroxychloroquine (5-10 mg/kg once daily) for 8 weeks, 7 months, and 9 months, respectively, with no side effects...
  56. pmc Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals
    Emileigh Mercer
    Division of Rheumatology, Brigham and Women s Hospital Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Arthritis Res Ther 14:R135. 2012
    b>Hydroxychloroquine (HCQ) is a common disease modifying therapy for the treatment of rheumatoid arthritis (RA). Prior research suggests that HCQ may reduce the risk of diabetes mellitus in patients with RA...
  57. pmc Optical coherence tomography in a patient with chloroquine-induced maculopathy
    Sanita Korah
    Department of Ophthalmology, Christian Medical College, Vellore, India
    Indian J Ophthalmol 56:511-3. 2008
    ..Parafoveal retinal thickness and volume measurements may be early evidence of chloroquine toxicity, and OCT measurements as a part of chloroquine toxicity screening may be useful in early detection of chloroquine maculopathy...
  58. ncbi Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome
    Markus Rihl
    Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany
    Rheumatology (Oxford) 48:796-9. 2009
    ..There is no established disease-modifying treatment of xerostomia and xerophthalmia in SS. This retrospective study was performed in order to evaluate the efficacy of HCQ for glandular function, i.e. saliva and tear production...
  59. pmc Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases
    Laura R Rekedal
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Arthritis Rheum 62:3569-73. 2010
    Prior research demonstrates that hydroxychloroquine (HCQ) lowers glycosylated hemoglobin (HbA(1c) ) in diabetes patients without rheumatic disease...
  60. ncbi Aurothiomalate and hydroxychloroquine inhibit nitric oxide production in chondrocytes and in human osteoarthritic cartilage
    K Vuolteenaho
    The Immunopharmacological Research Group, Medical School, University of Tampere, Tampere University Hospital, Finland
    Scand J Rheumatol 34:475-9. 2005
    ..The aim of the present study was to investigate the effect of disease-modifying anti-rheumatic drugs (DMARDs) on interleukin-1beta (IL-1beta)-induced NO production in chondrocyte cultures, and in human osteoarthritic cartilage...
  61. ncbi Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI)
    Naoto Yokogawa
    Tokyo Metropolitan Tama Medical Center, Section of Rheumatology, 2 8 29 Musashidai, Fuchu, Tokyo 183 8524, Japan
    Mod Rheumatol 22:249-55. 2012
    ..CLASI) in Japanese patients with systemic lupus erythematosus (SLE) in order to design a clinical trial of hydroxychloroquine (HCQ) in Japan...
  62. ncbi Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome
    Sule Yavuz
    Department of Rheumatology, Marmara University Medical School, Istanbul, Turkey
    Rheumatol Int 31:1045-9. 2011
    The objective of the study is to investigate the effect of hydroxychloroquine (HCQ) on subjective and objective parameters of dry eye in patients with primary Sjogren's disease and to evaluate the association of tear fluid B-cell ..
  63. ncbi Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus
    J A James
    Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Lupus 16:401-9. 2007
    ..One option for treatment in this setting is hydroxychloroquine. Using 130 US military personnel who later met ACR SLE criteria, a retrospective study of onset, development ..
  64. ncbi An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine
    O Brorson
    Department of Microbiology, Vestfold Sentralsykehus, Tønsberg, Norway
    Int Microbiol 5:25-31. 2002
    In this work the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine (HCQ) was studied...
  65. ncbi Assessing hydroxychloroquine toxicity by the multifocal ERG
    Michael N Moschos
    Department of Ophthalmology, University of Athens, Greece
    Doc Ophthalmol 108:47-53. 2004
    ..These results postulate that the mfERG may be used as an alternative method, perhaps more sensitive, for the detection of the HC retinopathy and the follow up of the patients on hydroxychloroquine.
  66. ncbi Kikuchi-Fujimoto disease: hydroxychloroquine as a treatment
    Katayoun Rezai
    Section of Infectious Diseases, Department of Medicine, John H Stroger Hospital of Cook County, Chicago, IL 60612, USA
    Clin Infect Dis 39:e124-6. 2004
    We describe a case of recurrent Kikuchi's disease in a South Asian-American man that was treated successfully with chloroquine and on recurrence with hydroxychloroquine. Each treatment led to a very prompt response.
  67. pmc Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus
    Sara Kaprove Penn
    Department of Medicine, Division of Rheumatology, University of Pittsburgh, School of Nursing, 440 Victoria Street, Room 453B, Pittsburgh, PA 15261, USA
    J Rheumatol 37:1136-42. 2010
    To determine the relationship between current hydroxychloroquine (HCQ) use and 2 indicators of glycemic control, fasting glucose and insulin sensitivity, in nondiabetic women with systemic lupus erythematosus (SLE) or rheumatoid arthritis ..
  68. ncbi Dramatic response of scarring scalp discoid lupus erythematosus (DLE) to intravenous methylprednisolone, oral corticosteroids, and hydroxychloroquine in a 5-year-old child
    Paivi M H Miettunen
    Division of Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Canada
    Pediatr Dermatol 26:338-41. 2009
    ..Histopathology confirmed the diagnosis of DLE. Treatment with intravenous methylprednisolone, hydroxychloroquine, oral prednisone, topical corticosteroids, and sunscreen lead to reversal of scarring alopecia and re-growth ..
  69. ncbi Controlled trial of hydroxychloroquine in schizophrenia
    Menelik Desta
    Amanuel Hospital Addis Ababa University Medical School, Ethiopia
    J Clin Psychopharmacol 22:507-10. 2002
    b>Hydroxychloroquine is widely employed for the treatment of rheumatological diseases...
  70. ncbi Papular elastolytic giant cell granuloma responding to hydroxychloroquine and quinacrine
    Benjamin J Kelly
    Division of Dermatology and Cutaneous Surgery, The Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Malcolm Randall Veterans Administration Medical Center, Gainesville, FL 32610 0277, USA
    Int J Dermatol 43:964-6. 2004
  71. ncbi [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses]
    K Rüther
    Charité Augenklinik Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin
    Ophthalmologe 104:875-9. 2007
    The critical dose of chloroquine/hydroxychloroquine leading to a maculopathy or generalised retinopathy remains undetermined. In the literature, 100 g is considered the dose at which regular vision checks should be performed...
  72. ncbi Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography
    Burak Turgut
    Department of Ophthalmology, Faculty of Medicine, Firat University, Elazig, Turkey
    Clin Rheumatol 28:607-9. 2009
    b>Hydroxychloroquine (HCQ) that is widely used in the treatment of the connective tissue disorders can cause retinopathy...
  73. pmc Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax
    Hyeong Seok Lim
    Department of Pharmacology, Ulsan University College of Medicine, Songpa Gu, Seoul, Republic of Korea
    Antimicrob Agents Chemother 53:1468-75. 2009
    b>Hydroxychloroquine (HCQ) is an antimalarial drug used as chemoprophylaxis against malaria caused by Plasmodium vivax in the Republic of Korea Army (ROKA)...
  74. pmc Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug
    Jacob H Rand
    Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
    Blood 115:2292-9. 2010
    ..We investigated whether the antimalarial drug, hydroxychloroquine (HCQ), might affect this prothrombotic mechanism...
  75. ncbi Hydroxychloroquine for subglottic stenosis: a novel therapy in the battle for air
    Nir Hirshoren
    Department of Otolaryngology Head and Neck Surgery, Hebrew University School of Medicine, Hadassah Medical Center, Jerusalem, Israel
    Laryngoscope 120:743-4. 2010
    ..b>Hydroxychloroquine interferes with antigen processing by means of raising lysosomal pH and immune response modulation...
  76. ncbi Hydroxychloroquine-induced myopathy
    Jun Beom Kwon
    Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Rheumatol 16:28-31. 2010
    ..She had been treated with hydroxychloroquine (HCQ) for last 5 years...
  77. ncbi Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus
    Nathalie Costedoat-Chalumeau
    Assistance Publique Hopitaux de Paris, Centre Hospitalier Universitaire Pitie Salpetriere, Universite Paris VI Pierre et Marie Curie, Paris, France
    Arthritis Rheum 54:3284-90. 2006
    To study the possible relationship between whole-blood hydroxychloroquine (HCQ) concentrations and clinical efficacy of HCQ in patients with systemic lupus erythematosus (SLE).
  78. ncbi Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis
    N Kasitanon
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, USA
    Lupus 15:366-70. 2006
    ..Eleven (38%) patients achieved complete renal remission by 12 months. Of those taking hydroxychloroquine, 7/11 (64%) were in remission within 12 months compared to only 4/18 (22%) of those not on hyroxychloroquine ..
  79. ncbi Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid antibody (Hughes') syndome
    Kam Hon Yoon
    J Rheumatol 29:1574-5. 2002
  80. ncbi Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts
    Bettina Ramser
    Department of Dermatology, University of Munster, Munster, Germany
    J Invest Dermatol 129:2419-26. 2009
    b>Hydroxychloroquine (HCQ) is a commonly used therapeutic agent in skin disorders. Some reports also suggest that HCQ can be useful in fibroblastic diseases of the skin...
  81. ncbi Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy
    J Comin-Colet
    Department of Cardiology, Hospital Princeps d Espanya, Ciutat Sanitaria i Universitaria de Bellvitge, Barcelona, Spain
    Lupus 10:59-62. 2001
    ..CHB in the context of an acute flare-up of SLE, first diagnosed three years ago, having recently commenced hydroxychloroquine (HCQ) treatment. Anti-Ro and anti-RNP antibodies were also positive. No features of myocarditis were found...
  82. pmc Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort
    Guillermo J Pons-Estel
    University of Alabama at Birmingham, USA
    Arthritis Care Res (Hoboken) 62:393-400. 2010
    ..To determine the features predictive of time to integument damage in patients with systemic lupus erythematosus (SLE) from a multiethnic cohort (LUpus in MInorities, NAture versus nurture [LUMINA])...
  83. ncbi Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus
    Michelle T Pelle
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Arch Dermatol 138:1231-3; discussion 1233. 2002
    b>Hydroxychloroquine sulfate and other antimalarial drugs have been used successfully as adjunctive therapy for patients with cutaneous lesions of dermatomyositis over the past 20 years...
  84. ncbi In vivo confocal microscopy in hydroxychloroquine-induced keratopathy
    Andre Dosso
    University Eye Clinic, 22 rue Alcide Jentzer, 1211 Geneva 14, Switzerland
    Graefes Arch Clin Exp Ophthalmol 245:318-20. 2007
    ..Vortex keratopathy, arising as a side effect of several medications, is characterized by golden-brown deposits in the cornea...
  85. ncbi Hydroxychloroquine-induced hyperpigmentation: the staining pattern
    Puja K Puri
    Department of Dermatology Dermatopathology, Geisinger Medical Center, Danville, PA 17822, USA
    J Cutan Pathol 35:1134-7. 2008
    We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day...
  86. pmc Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort
    Guillermo J Pons-Estel
    University of Alabama at Birmingham
    Arthritis Rheum 61:830-9. 2009
    To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients.
  87. pmc Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus
    Nathalie Costedoat-Chalumeau
    AP HP, Service de Medecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, CHU Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Ann Rheum Dis 66:821-4. 2007
    Poor adherence to treatment is difficult to diagnose accurately. Hydroxychloroquine (HCQ) has a long elimination half-life and its concentration in whole blood can be measured easily.
  88. ncbi Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease
    Vicente Giner Galvan
    Department of Internal Medicine, Hospital Clinico Universitario, University of Valencia, Valencia, Spain
    Clin Rheumatol 26:971-2. 2007
    ..b>Hydroxychloroquine (HCQ), a alpha-hydroxylated derivative of chloroquine, is usually preferred because of its higher ..
  89. ncbi Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy
    Timothy Y Y Lai
    Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong
    Doc Ophthalmol 112:177-87. 2006
    To evaluate the effects of hydroxychloroquine on visual field and multifocal electroretinography (mfERG) and their correlations in patients taking hydroxychloroquine.
  90. ncbi Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates
    Radouil Tzekov
    Biological Sciences, RD2 2C Allergan Inc, 2525 Dupont Drive, Irvine, CA 92612, USA
    Doc Ophthalmol 110:111-20. 2005
    ..A summary and comment on the tests, with emphasis on the use of more recently developed methods, such as the multifocal electroretinography (mfERG), are presented in this review...
  91. ncbi Survival after massive hydroxychloroquine overdose
    N Gunja
    New South Wales Poisons Information Centre, The Children s Hospital at Westmead, Sydney, New South Wales, Australia
    Anaesth Intensive Care 37:130-3. 2009
    b>Hydroxychloroquine overdose is infrequently reported and the majority of recommendations come from the greater experience with chloroquine poisoning...
  92. ncbi Hydroxychloroquine and surfactant protein C deficiency
    Dennis M Rosen
    N Engl J Med 352:207-8. 2005
  93. ncbi Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis
    Tino Munster
    University of Erlangen, Erlangen, Germany
    Arthritis Rheum 46:1460-9. 2002
    A dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement, had previously been observed in patients with rheumatoid arthritis (RA) receiving a 6-..
  94. ncbi Hydroxychloroquine in systemic lupus erythematosus
    Nathalie Costedoat-Chalumeau
    Lancet 369:1257-8. 2007
  95. ncbi Treatment of lupus skin involvement with quinacrine and hydroxychloroquine
    I Cavazzana
    Rheumatology Unit and Chair A O Spedali Civili di Brescia Università degli Studi di Brescia, Italy
    Lupus 18:735-9. 2009
    To evaluate the efficacy of hydroxychloroquine (HCQ) and quinacrine (Qn) association, at two different dosages, in treatment of lupus skin lesions not responding to HCQ alone...
  96. ncbi Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea
    Sei Won Lee
    Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Republic of Korea
    Am J Trop Med Hyg 81:600-4. 2009
    The Republic of Korea (ROK) Army instituted a vivax malaria chemoprophylaxis program (hydroxychloroquine [HCQ] 400 mg per week) in 1997 that was expanded to nearly 200,000 soldiers by 2007, raising concerns for the emergence of drug-..
  97. ncbi Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system
    Charles Chiang
    Department of Dermatology at University of California, San Francisco, California 94143, USA
    J Am Acad Dermatol 62:387-92. 2010
    ..Lichen planopilaris (LPP) and its variant frontal fibrosing alopecia (FFA) are primary lymphocytic cicatricial alopecias for which there is no evidence-based therapy...
  98. ncbi Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase
    L J Dawson
    Clinical Dental Sciences, University of Liverpool, UK
    Rheumatology (Oxford) 44:449-55. 2005
    ..pSS), (ii) increased levels of cholinesterase of lymphocyte origin could interfere with the secretory activity of submandibular acinar cells, and (iii) hydroxychloroquine at therapeutic doses could interfere with cholinesterase activity.
  99. ncbi Hydroxychloroquine-induced DRESS syndrome
    Alessandro Volpe
    Department of General Medicine, Sacro Cuore Hospital, Via Sempreboni 5, Negrar, VR, Italy
    Clin Rheumatol 27:537-9. 2008
    The authors describe the first case of drug rash with eosinophilia and systemic symptoms syndrome caused by hydroxychloroquine treatment in a male patient affected by seronegative arthritis.
  100. ncbi Evidence of transplacental passage of hydroxychloroquine in humans
    Nathalie Costedoat-Chalumeau
    Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Arthritis Rheum 46:1123-4. 2002
  101. ncbi Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine
    Ulrich Kellner
    AugenZentrum Siegburg, Siegburg, Germany
    Invest Ophthalmol Vis Sci 47:3531-8. 2006
    To evaluate and compare the value of fundus autofluorescence (FAF) imaging and multifocal electroretinography (mfERG) in early detection of retinal alterations in patients using chloroquine/hydroxychloroquine (CQ/HCQ).

Research Grants39

  1. Immune tolerance in the therapy of rheumatoid arthritis
    Salvatore Albani; Fiscal Year: 2010
    ..This is particularly evident in patients pre-treated with hydroxychloroquine (HCQ). These patients had a better clinical response to the dnaJP1 treatment...
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
    ..Retinal Toxicity, with Evaluation of the ABCA4 Gene Number: 10-EI-0140 Summary: Background: - Plaquenil (hydroxychloroquine) is an anti-inflammatory drug that is used to treat some autoimmune diseases such as lupus and rheumatoid ..
  3. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..Retinal Toxicity, with Evaluation of the ABCA4 Gene Number: 10-EI-0140 Summary: Background: - Plaquenil (hydroxychloroquine) is an anti-inflammatory drug that is used to treat some autoimmune diseases such as lupus and rheumatoid ..
  4. Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH)
    JILL PAMELA BUYON; Fiscal Year: 2013
    ..Subsequent translation to patients was approached by evaluating hydroxychloroquine (HCQ) use in an extensive case control study restricted to lupus mothers and a separate retrospective ..
  5. HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition
    Ravi K Amaravadi; Fiscal Year: 2013
    ..Numerous clinical trials are testing the combination of variety of anticancer agents with hydroxychloroquine (HCQ), but there currently is no biomarker that can focus the development of HCQ combinations or regimens ..
  6. A Phase 0 Trial of Hydroxychloroquine in Patients with Stage III and IV Resectabl
    Janice Mehnert; Fiscal Year: 2010
    ..b>Hydroxychloroquine (HCQ) is a drug that blocks autophagy, raising intralysosomal pH and inhibiting the final step of this ..
  7. Understanding early events in lupus autoimmunity to aid prevention
    Judith A James; Fiscal Year: 2013
    ..SLE are found o have dysregulation of select cytokines and chemokines years before disease onset and hydroxychloroquine has been associated with a delayed onset of SLE classification and slowed autoantibody accrual...
  8. Inhibition of Autophagy: A Novel Therapeutic Strategy for Advanced Solid Tumors
    Francis J Giles; Fiscal Year: 2010
    ..We recently established that the antimalarial drugs chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) inhibit autophagy and significantly increase the efficacy of the histone deacetylase inhibitor ..
  9. Investigating the Role of Autophagy in Pancreatic Cancer Radiation Resistance
    Alec Kimmelman; Fiscal Year: 2013
    ..Since potent autophagy inhibitors, such as chloroquine (CQ) and hydroxychloroquine (HCQ), are available and FDA approved, this work has immediate clinical application to the treatment of PDAC ..
  10. Cardiovascular Inflammation Reduction Trial (CIRT): DCC
    Robert J Glynn; Fiscal Year: 2013
    ..the confounding effects on lipids, glucose, and thrombosis that significantly limit other agents including hydroxychloroquine. The potential clinical impact of this trial is broad as it has sufficient power to directly address core ..
  11. Cardiovascular Inflammation Reduction Trial (CIRT)
    Paul M Ridker; Fiscal Year: 2013
    ..the confounding effects on lipids, glucose, and thrombosis that significantly limit other agents including hydroxychloroquine. The potential clinical impact of this trial is broad as it has sufficient power to directly address core ..
  12. Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes
    Frederico G S Toledo; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes. Diabetes is approaching epidemic proportions in the United States...
  13. Improving current therapies for myeloma
    DAN TOBY VOGL; Fiscal Year: 2013
    ..Recent basic science laboratory work done by my collaborators has identified hydroxychloroquine as a potent inhibitor of autophagy in malignant cells...
  14. Autophagy inhibition as a therapeutic strategy for glioblastoma mutliforme
    Ravi Amaravadi; Fiscal Year: 2009
    ..These studies found that the lysosomotropic antimalarial hydroxychloroquine(HCQ) can inhibit therapy-induced autophagy and enhance tumor cell death...
  15. Therapeutic approaches that target cancer cell metabolism
    Ravi K Amaravadi; Fiscal Year: 2012
    ..The second aim will be the completion of the preclinical evaluation of hydroxychloroquine using xenograft tumor models followed by Phase I and Phase II clinical trials of hydroxychloroquine in ..
  16. Autophagy inhibition to sensitize colon cancer to anti-angiogenic therapy
    PETER J O'DWYER; Fiscal Year: 2013
    ..In parallel with this analysis in preclinical models, we propose a direct translation to the clinic, with a trial of hydroxychloroquine in combination with standard therapy for colorectal cancer.
  17. Treatment of Early Aggressive Rheumatoid Arthritis TEAR
    Larry Moreland; Fiscal Year: 2001
    ..is a 3-arm study comparing 2 different combinations (anti-TNF plus methotrexate versus methotrexate plus hydroxychloroquine plus sulfasalazine) versus monotherapy (methotrexate) in patients with early RA who have an "aggressive" ..
  18. HYDROXYCHLOROQUINE THERAPY AND BIOLOGY OF GVHD
    Andrew Gilman; Fiscal Year: 2004
    ..The proposed study will examine the benefit of adding hydroxychloroquine (HCQ) to standard therapy for the treatment of newly diagnosed extensive chronic GVHD...
  19. Meaningful Outcome Measures for Pediatrc Lupus Trials
    Hermine Brunner; Fiscal Year: 2006
    ..Children with cSLE have a worse prognosis than adults. There are only 3 medications (aspirin, hydroxychloroquine, gluco-corticoids) that have ever been fully approved for adult SLE by the U.S...
  20. Meaningful Outcome Measures for Pediatric Lupus Trials
    Hermine Brunner; Fiscal Year: 2004
    ..Children with cSLE have a worse prognosis than adults. There are only 3 medications (aspirin, hydroxychloroquine, gluco-corticoids) that have ever been fully approved for adult SLE by the U.S...
  21. Predictors of Treatment Response in Early Aggressive RA
    S Bridges; Fiscal Year: 2007
    ..RA include disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and the TNF inhibitor etanercept. Multiple new biologic agents currently in development...
  22. Rheumatoid Arthritis: Predictors of Therapeutic Response
    JAMES O DELL; Fiscal Year: 2002
    ..Retrospective analysis of this information can be utilized to plan prospective clinical trials using potentially predictive patterns of cytokine, matrix metalloproteinases, and genetic factors. ..
  23. Reduction of Annexin A5 in Antipholipid Pregnancy Loss
    JACOB RAND; Fiscal Year: 2010
    ....
  24. Brain Connections
    Michelle Petri; Fiscal Year: 2006
    ..abstract_text> ..
  25. Revision of ACR Classification Criteria for Systemic Lupus Erythematosus
    Michelle Petri; Fiscal Year: 2007
    ..This project will lead to updated, validated SLE classification criteria that can be immediately used by both industry and academic clinical trials. ..
  26. Genetic Polymorphisms in Rheumatoid Arthritis
    Eric Matteson; Fiscal Year: 2004
    ..The mentorship program proposed in this grant is critical to this long-term goal. ..
  27. OUTCOME OF SYSTEMIC LUPUS ERYTHEMATOSUS IN MINORITIES
    GRACIELA ALARCON; Fiscal Year: 2004
    ....
  28. Cognitive dysfunction in neuropsychiatric-SLE
    Michael Lockshin; Fiscal Year: 2002
    ..Successful completion of this research will redefine the pathogenesis of cognitive dysfunction and suggest therapeutic targets for intervention...
  29. AUTOIMMUNE MECHANISMS OF THROMBOSIS
    Robert Roubey; Fiscal Year: 2004
    ..These data will be useful in focusing future research efforts on specific pathways of antibody-mediated monocyte activation and hypercoagulability and in designing new therapeutic strategies...
  30. Eliciting Patient Treatment Preferences for Osteoporosis
    Liana Fraenkel; Fiscal Year: 2008
    ..abstract_text> ..
  31. AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM
    David Aboulafia; Fiscal Year: 2005
    ..5. Assist the AMC and the NCI clinical trials cooperative groups and the NIAID ACTUs in the development and implementation of phase III studies if initial efforts of the AMC consortium are successful. ..
  32. Therapeutic use of inhibitory DNA sequences in animal models of lupus
    Petar Lenert; Fiscal Year: 2006
    ..Future extension of these studies to humans may lead to the design of novel therapeutic agents for human SLE. [unreadable] [unreadable] [unreadable]..
  33. LYME ARTHRITIS: A NEW EPIDEMIC DISEASE
    Allen C Steere; Fiscal Year: 2010
    ..Furthermore, this work brings us closer to the long-term goal of direct comparisons of antigens in Lyme arthritis and rheumatoid arthritis synovia. ..
  34. Development of Novel Therapeutic Strategy for Sickle Ce*
    EMFEMWONKIEKIE IYAMU; Fiscal Year: 2007
    ..Such an environment maximizes the potential for the P.I. to establish a scientific niche from which an academic career can be constructed. [unreadable] [unreadable]..
  35. Impact of Medications on Outcomes in Lupus
    Barri Fessler; Fiscal Year: 2008
    ..Recent evidence suggests that hydroxychloroquine may be such a medication...
  36. Mechanism of Action of Inhibitory CpG Oligonucleotides
    Petar Lenert; Fiscal Year: 2009
    ..abstract_text> ..
  37. Diagnosis and Pathogenesis of Early Lyme Disease
    Allen Steere; Fiscal Year: 2007
    ..In addition, greater knowledge of spirochetal virulence and host factors associated with severe disease may allow the development of laboratory markers for patients who would benefit from more intensive treatment. ..
  38. Clinical Basis Investigations into MLS/Leopard Syndrome
    Theresa Pacheco; Fiscal Year: 2007
    ..D. is an Assistant Professor of Dermatology and is committed to a career in clinical research with an focus on molecular markers of disease (pigmentation anomalies) and patient-oriented research topics. ..